[1] |
LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan.
Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785.
|
[2] |
CAO Kai, QIAN Peipei, GAO Xin, YANG Futian, ZHAO Liang, XU Bingxin, ZHANG Xianjun.
Mining of Risk Signals Adverse Events Related to Drug-Induced Salivary Gland Calculus Based on FAERS Database
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 799-804.
|
[3] |
LIANG Fanglin, CHEN Lingyuan, HU Danli, WEI Lingyun, WEI Tiemeng, ZHANG Faen, WEI Yana.
Immune-Related Adverse Events of Tislelizumab in 120 Patients with Hepatocellular Carcinoma
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 659-663.
|
[4] |
CHEN Lingbin, HUANG Zhixiong, ZHENG Cailin, WU Jinneng, CHEN Zhou.
Adverse Event Signals for Osimertinib-Induced Muscle Toxicity Based on FAERS Database
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 447-451.
|
[5] |
SUN Yixin, WANG Chen, YU Yuelin, GUO Peng, NIE Xiaolu.
Safety Surveillance for Vaccine-Induced Immune Thrombotic Thrombocytopenia: a Systematic Review
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 29-36.
|
[6] |
HOU Tiantian, WANG Xudong, YANG Ping, ZHOU Pengbo, QIN Chao, HUANG Ying, WANG Ailing, GENG Xingchao, ZHOU Xiaobing, LIU Defang.
Biodistribution of Therapeutic DNA Vaccines in Mice
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 58-66.
|
[7] |
LIU Nannan, XI Yalin, CHEN Zhe.
One Case of Adrenocortical Insufficiency Caused by Cadonilimab
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 109-112.
|
[8] |
ZHONG Hong, CHEN Hong, ZHANG Xuanyi, DENG Huiyuan, LUO Xianglin, WAN Jie, KONG Wenqiang.
Detection and analysis of signals of adverse events induced by deferasirox based on FAERS
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 931-935.
|
[9] |
XIA Lanfang, LI Keli, WANG Lei, LI Yan, WANG Huaqing.
Impact of comparator selection on signal detection in adverse events following immunization in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 798-804.
|
[10] |
LIU Yan, AN Jing, JIAO Yongzhuo, LIANG Xuefeng, ZHANG Xiaoshu.
Simple febrile seizures within 30 days of vaccination with the measles, mumps and rubella combined attenuated live vaccine in U-12 children in the real world
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 805-810.
|
[11] |
NIE Xiaolu, MA Jingyao, SUN Feng, ZHAN Siyan.
Pathogenesis and diagnosis of drug-induced thrombocytopenia
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 829-835.
|
[12] |
WU Yi, HE Jinyang, WANG Xiaojian, ZhOU Xiaozhu, LIU Ranjia, GUO Mingxing, ZHAO Ying, DAI Wendi, CUI Xiangli.
Adverse events of COVID-19 vaccination in recipients of liver and kidney transplant based on US VAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 572-579.
|
[13] |
ZHANG Jian, ZHANG Lingli, LI Xin.
Immune-related adverse events of tirelizumab in 424 cases of cancer patients
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 435-439.
|
[14] |
YOU Xiaoyan, ZHENG Yingying, WANG Xianying.
Data-mining and analysis of adverse events signals for infliximab based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 335-340.
|
[15] |
WU Tingxi, ZHAO Zhigang, SHI Yanfeng, ZHANG Yang, ZHANG Yinan, ZHU Bin.
Risk assessment of colchicine-associated neurological adverse events based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 341-345.
|